MedTrace Logo

Study of Nitazoxanide in the Treatment of Chronic Hepatitis C

NCT00418639 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2007-01-05

No results posted yet for this study

Summary

This study will evaluate the effect of treatment with 24 weeks nitazoxanide monotherapy on end of treatment virologic response, sustained virologic response, reduction of quantitative serum HCV RNA, changes in ALT and safety parameters.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Nitazoxanide

Sponsors & Collaborators

  • Romark Laboratories L.C.

    lead INDUSTRY

Principal Investigators

  • Samir M Kabil, MD · Cairo Liver & GIT Center

  • Yehia El-Gohary, MD · Department of Tropical Medicine & Infectious Diseases, Alexandria University

  • Asem Elfert, MD · Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00418639 on ClinicalTrials.gov